🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
27/03/2017 16,46 16,55 16,35 16,44 +0,55% 1,22% 7.690
24/03/2017 16,55 16,55 16,35 16,35 -1,21% 1,21% 11.588
23/03/2017 16,50 16,63 16,26 16,55 +1,22% 2,24% 6.009
22/03/2017 16,08 16,46 16,08 16,35 +0,62% 2,36% 4.872
21/03/2017 16,21 16,50 16,15 16,25 +0,25% 2,16% 18.057
20/03/2017 16,21 16,21 16,10 16,21 +1,19% 0,68% 3.087
17/03/2017 16,25 16,25 16,00 16,02 -1,42% 1,54% 6.788
16/03/2017 16,40 16,40 16,01 16,25 +0,81% 2,38% 2.263
15/03/2017 16,37 16,37 16,00 16,12 +0,06% 2,26% 6.282
14/03/2017 16,45 16,45 16,11 16,11 -0,56% 2,07% 2.813
13/03/2017 16,41 16,41 16,11 16,20 +1,25% 1,83% 3.194
10/03/2017 16,31 16,38 16,00 16,00 -1,90% 2,33% 56.822
09/03/2017 16,60 16,69 16,31 16,31 -1,51% 2,29% 8.730
08/03/2017 16,70 16,72 16,56 16,56 -0,84% 0,96% 1.992
07/03/2017 16,60 16,72 16,50 16,70 +0,85% 1,33% 12.943
06/03/2017 16,49 16,71 16,41 16,56 +0,91% 1,82% 20.615
03/03/2017 16,19 16,43 16,00 16,41 +2,56% 2,66% 17.661
02/03/2017 15,85 16,20 15,62 16,00 +1,59% 3,66% 28.567
01/03/2017 15,62 15,75 15,28 15,75 +3,89% 3,01% 8.004
28/02/2017 15,48 15,89 15,13 15,16 -0,26% 4,91% 10.355
27/02/2017 14,80 15,25 14,80 15,20 +2,49% 3,04% 13.847
24/02/2017 14,86 15,00 14,75 14,83 -0,20% 1,68% 8.362
23/02/2017 15,09 15,09 14,80 14,86 +0,07% 1,92% 21.236
22/02/2017 14,85 15,09 14,75 14,85 +0,13% 2,29% 20.946
21/02/2017 15,25 15,25 14,83 14,83 -2,75% 2,75% 7.798
20/02/2017 15,27 15,64 15,25 15,25 -0,26% 2,55% 4.746
17/02/2017 15,12 15,93 15,12 15,29 +0,39% 5,36% 6.386
16/02/2017 15,45 15,45 15,20 15,23 -0,46% 1,62% 8.771
15/02/2017 15,31 15,74 15,30 15,30 -0,78% 2,87% 68.475
14/02/2017 15,98 15,98 15,41 15,42 -2,41% 3,57% 15.388